Q-omics provides the consensus-scored ME1 profile across patient tissues and cancer cell-line models. ME1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ME1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ME1 protein abundance shows 26,692 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight UVM, THCA, and CCRCC as cancer lineages where ME1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ME1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ME1 survival associations across molecular data types. ME1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ME1 RNA expression–survival associations across cancer types. High ME1 expression shows unfavorable associations in UVM, UCEC, LIHC, KIRP, STAD and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ME1 RNA expression.
This table summarizes ME1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 10. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ME1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ME1 shows lower tumor expression in THCA, BRCA and KICH and higher tumor expression in COAD, KIRP and LIHC. The THCA box plot shows higher ME1 RNA expression in normal versus tumor tissue (log2 FC = −2.512, t-test p < 0.001).
This table shows molecular features associated with ME1 in patient tissues and cancer cell lines. In patient samples, ME1 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ME1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SOFT_TISSUE.
